Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis-Reference-Cited by-同舟云学术

Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis

Published:2015-07-04 Issue:1 Volume:15 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Capdevila Jaume,Sevilla Isabel,Alonso Vicente,Antón Aparicio Luís,Jiménez Fonseca Paula,Grande Enrique,Reina Juan José,Manzano José Luís,Alonso Lájara Juan Domingo,Barriuso Jorge,Castellano Daniel,Medina Javier,López Carlos,Segura Ángel,Carrera Sergio,Crespo Guillermo,Fuster José,Munarriz Javier,García Alfonso Pilar

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/article/10.1186/s12885-015-1512-6/fulltext.html

Reference26 articles.

1. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):1–18. vii.

2. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61(1):6–32.

3. Phan AT, Oberg K, Choi J, Harrison Jr LH, Hassan MM, Strosberg JR, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010;39(6):784–98.

4. Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet JF, et al. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol. 2010;17(3):49–64.

5. Garcia-Carbonero R, Salazar R, Sevilla I, Isla D. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS). Clin Transl Oncol. 2011;13(8):545–51.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does the dose matter? Antiproliferative efficacy and toxicity of everolimus in patients with neuroendocrine tumors – Experiences from a tertiary referral center;Journal of Neuroendocrinology;2023-07-23

2. Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives;World Journal of Gastrointestinal Surgery;2022-02-27

3. Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor;Clinical Cancer Research;2022-01-11

4. Target therapies plus somatostatin analogs in NETs: a network meta-analysis;Endocrine-Related Cancer;2021-07-01

5. Everolimus therapy and side‑effects: A systematic review and meta‑analysis;International Journal of Oncology;2021-06-15